Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...

CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk and ORA officially seal their partnership to revolutionize obesity care in the Philippines through telehealth.

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

SINGAPORE] Locally headquartered biotech firm KPB Biosciences has failed to set aside a court order for its assets to be ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Novo Nordisk will invest around $1 billion to expand its production site in Montes Claros, Brazil, marking one of the largest pharmaceutical investments in the nation’s history. The company’s ...